PHAS News and Press, PhaseBio Pharmaceuticals Inc. From 09/15/21

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its board of directors. Additionally...

VANCOUVER, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended J...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provide a company overview at the ...

XtalPi, a US-China AI-based drug discovery company, completed a $400 million Series D financing at an estimated valuation of $2 billion. Shanghai's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers. Advaccine...

Entered exclusive licensing agreement with Alfasigma S.p.A with up to $245 million in milestone payments and tiered royalty payments for development and commercialization of bentracimab in European and other key markets Achieved interim enrollment milestone with first 143 bent...

First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year Enrollment of patients in the REVERSE-IT trial requiring urgent surgery or invasive procedure now complete, with trial focus shifting to enrollment of...

Enrollment in the REVERSE-IT global Phase 3 trial from clinical sites in China expected to begin later in 2021 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies fo...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside cha...

PhaseBio Pharmaceuticals (PHAS) has entered into an exclusive licensing agreement with Alfasigma S.p.A for the commercialization of bentracimab.Shares up more than 20% premarket.Under the terms of the license agreement, PhaseBio will receive a $20M upfront payment and will...

Agreement provides PhaseBio with $20 million upfront payment and eligibility to receive up to $245 million in development and commercial milestones in addition to tiered double digit royalties on sales Collaboration reinforces global bentracimab opportunity Establishes...